engleski

Selective targeting of photodynamic sensitisers to tumour tissue

A wide range of PDT sensitisers are now available and these vary in wavelength of activation, physicochemical properties and photodynamic activity in vivo. One parameter critical to the clinical outcome of PDT is the localised concentration of photosensitiser in the target tissue at the time of treatment, and the relative ratio of this tumoural concentration to that in surrounding peritumoural tissue. Most PDT sensitisers currently used in the clinic have relatively poor tumour: peritumoural tissue ratios, with values for intravenously administered drug very rarely achieving >100: (1) significant improvements in this important parameter, and hence clinical outcomes, are unlikely to be achieved by simple manipulation of photosensitiser structure. It may be possible, however, by the use of delivery vehicles, such as liposomes and/or covalent attachment of the photosensitiser to biologically active molecules with affinity for cell surface structures that are over-expressed on tumour tissue. In this paper the requirements for targeting will briefly be discussed and in vitro, mechanistic, and in vivo data relating to bioconjugates of PDT sensitisers with monoclonal antibodies will be presented.

Photodynamic therapy ; Porphyrin ; Bioconjugation

Rad/časopois je indeksiran i u: JCR/Science Edition ; National Library of Medicine.